



Quidel Introduces New Urinalysis Diagnostic Product, The UrinQuick(TM) Urine Chemistry Analyzer

July 30, 2002

ORLANDO, Fla., Jul 30, 2002 /PRNewswire-FirstCall via COMTEX/ -- Quidel Corporation (Nasdaq: QDEL), a leading provider of rapid point of care (POC) diagnostic tests, raised the bar today in urinalysis testing with the introduction at the American Association for Clinical Chemistry's (AACC) 54th Annual Meeting and Clinical Lab Expo of its new state-of-the-art urinalysis instrument, the UrinQuick(TM) Urine Chemistry Analyzer. Urinalysis testing has never been so easy as it is now with UrinQuick's advanced software capabilities and its newly patented transport and optic systems. Extremely user-friendly screens guide the laboratory personnel through every aspect of operation including a first in instruments of this class, a full on-board quality control program. The addition of the UrinQuick Urine Chemistry Analyzer expands Quidel's popular QuickVue line of high-quality, easy-to-use, point-of-care diagnostic products and marks the company's entry into the instrumentation market.

"Quidel's Urine Chemistry Analyzer is designed to be an easy and intuitive urinalysis instrument, allowing for high efficiency and cost-effectiveness," said Bill Elliott, executive vice president for Quidel. "The UrinQuick Urine Chemistry Analyzer is intended to offer the industry the ability to be more productive and efficient, which will in turn lead to lower operational costs."

The UrinQuick analyzer follows Quidel's August 2000 launch of QuickVue(R) UrinChek(R) urine test strips. Laboratorians can now analyze entire batches of urines easier and less expensively to detect the presence of ten important health markers that assist in the diagnosis of diabetes, liver and kidney disease, urinary tract infections and other ailments.

"Today's market is crying out for diagnostic products that reduce lab analysis cycles and lower costs without sacrificing quality," said S. Wayne Kay, president and chief executive officer of Quidel. "Diagnostic tools such as UrinQuick and others offered by Quidel are in direct response to these pressing market needs and will help physicians throughout the country better serve their patients."

About Quidel

Quidel Corporation, a worldwide company helping women and their families live healthy lives, discovers, develops, manufactures and markets rapid point-of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions associated with women's health in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, Strep throat, H. pylori infection, chlamydia, infectious mononucleosis and bacterial vaginosis. Quidel's products are sold to healthcare professionals for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information that enables rapid treatment and improves health outcomes, lowers costs and increases patient satisfaction. For more information, please visit Quidel's Web site at <http://www.quidel.com>.

This press release contains forward-looking statements regarding Quidel's future activities within the meaning of the federal securities laws. These forward-looking statements involve material risks and uncertainties. Many possible factors could affect the future results and performance of Quidel's products, such that actual results and performance may differ materially. If Quidel's products fail to perform as expected, or if there is lower consumer demand for these products than expected, Quidel's financial condition and operating results may be materially and adversely affected. Quidel's financial condition and operating results may also be materially and adversely affected by a number of other factors, including, without limitation, seasonality, adverse changes in competitive and economic conditions, actions by the Company's distributors, manufacturing and production delays or difficulties and adverse actions or delays in product reviews by the FDA. Please see the discussion of these and other factors in Quidel's annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. For more information, please visit Quidel's web site at <http://www.quidel.com>.

CONTACT:

media, Bea Evangelista of Euro RSCG Middleberg,
+1-212-699-2503, bea.evangelista@eurorscg.com, for Quidel; or Paul E. Landers,
Vice President & Chief Financial Officer of Quidel Corporation,
+1-858-552-7962; or investors, Ina McGuinness of Lippert/Heilschorn,
+1-310-691-7105, imcguinness@lhai.com, for Quidel